IRVINE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend the 24th Annual Needham Virtual Healthcare Conference, taking place from April 7-10, 2025.

加利福尼亚州尔湾市，2025年4月2日（环球新闻社）——领先的诊断技术公司Oncocyte Corp.（纳斯达克股票代码：OCX）今天宣布，首席执行官乔希·里格斯和首席财务官安德烈娅·詹姆斯将出席于2025年4月7日至10日举行的第24届Needham年度虚拟医疗保健会议。

In addition, CEO Josh Riggs will participate in a fireside chat at the conference..

此外，首席执行官乔什·里格斯将参与会议的炉边谈话。

During the event, Josh and Andrea will discuss Oncocyte’s innovative diagnostic technologies and will highlight the company’s progress toward commercializing a regulated organ transplant rejection monitoring test kit. The company is pursuing a market-disruptive approach, positioning Oncocyte to lead the way in advancing transplant monitoring solutions..

在本次活动期间，Josh 和 Andrea 将讨论 Oncocyte 的创新诊断技术，并重点介绍公司在将受监管的器官移植排斥监测试剂盒商业化方面取得的进展。该公司正在采取一种颠覆市场的策略，旨在使 Oncocyte 成为推进移植监测解决方案的领军者。

Investors wishing to attend the virtual fireside chat or schedule one-on-one meetings are encouraged to reach out to their Needham sales representative to express interest.

希望参加虚拟炉边谈话或安排一对一会议的投资者，可联系他们的 Needham 销售代表表达兴趣。

Event:

事件：

24th Annual Needham Virtual Healthcare Conference

第24届Needham年度虚拟医疗保健会议

Dates:

日期：

April 7-10, 2025

2025年4月7日至10日

Oncocyte Fireside Chat:

Oncocyte炉边谈话：

April 7, 2025, 3:45 PM (ET)

2025年4月7日，下午3点45分（东部时间）

Location:

位置：

Virtual

虚拟的

For more information about Oncocyte and its products, please visit

有关Oncocyte及其产品的更多信息，请访问

www.oncocyte.com

www.oncocyte.com

.

。

About Oncocyte

关于Oncocyte

Oncocyte is a diagnostics technology company. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a clinical blood-based solid organ transplantation monitoring test. GraftAssure™ is a research use only (RUO) blood-based solid organ transplantation monitoring test.

Oncocyte是一家诊断技术公司。该公司测试旨在帮助为医生及其患者提供清晰度和信心。VitaGraft™ 是一种基于临床血液的实体器官移植监测测试。GraftAssure™ 是一种仅供研究使用的（RUO）基于血液的实体器官移植监测测试。

DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI™ is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients..

DetermaIO™ 是一种基因表达测试，可评估肿瘤微环境以预测对免疫疗法的反应。DetermaCNI™ 是一种基于血液的监测工具，用于监测癌症患者的治疗效果。

For more information about our products, please visit the following web pages:

有关我们产品的更多信息，请访问以下网页：

VitaGraft Kidney™ -

维塔格拉夫特肾脏™ -

https://oncocyte.com/vitagraft-kidney/

https://oncocyte.com/vitagraft-kidney/

VitaGraft Liver™ -

维塔格拉夫特肝脏™ -

https://oncocyte.com/vitagraft-liver/

https://oncocyte.com/vitagraft-liver/

GraftAssure™ -

GraftAssure™ -

https://oncocyte.com/graftassure/

https://oncocyte.com/graftassure/

DetermaIO™ -

DetermaIO™ -

https://oncocyte.com/determa-io/

https://oncocyte.com/determa-io/

DetermaCNI™ -

DetermaCNI™ -

https://oncocyte.com/determa-cni/

https://oncocyte.com/determa-cni/

VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation.

VitaGraft™、GraftAssure™、DetermaIO™ 和 DetermaCNI™ 是 Oncocyte Corporation 的商标。

Forward-Looking Statements

前瞻性声明

Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” “may,” and similar expressions) are forward-looking statements. These statements include those pertaining to, among other things, Oncocyte’s progress toward commercializing a regulated organ transplant rejection monitoring test kit, and other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management.

任何非历史事实的陈述（包括但不限于含有“将”、“相信”、“计划”、“预期”、“预计”、“可能”及类似表达的陈述）均为前瞻性陈述。这些陈述包括有关Oncocyte在商业化受监管的器官移植排斥监测试剂盒方面的进展，以及其他关于管理层表达的未来预期、信念、目标、计划或前景的陈述。

Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of Oncocyte’s third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to supply chains, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, obligations to third parties with respect to licensed or acquired technology and products, the need to obtain third party reimbursement for patients’ use of any diagnostic tests Oncocyte or its subsidiaries commercialize in applicable jurisdictions, and risks inherent in strategic transactions such as the potential failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, potential greater than estimated allocations of resources to develop and commercialize technologies, or potential failure to maintain any laboratory accreditation or certification.

前瞻性声明涉及风险和不确定性，包括但不限于：与诊断测试或产品开发和/或商业化相关的固有风险、临床试验结果或监管审批的不确定性、Oncocyte的第三方供应的血液样本分析系统在商业规模上提供一致且精确分析结果的能力、供应链潜在中断、未来获取资本的需求和能力、在所有适用司法管辖区维护知识产权权利、与授权或收购技术及产品相关的对第三方的义务、在适用司法管辖区获取第三方对患者使用任何Oncocyte或其子公司商业化的诊断测试进行报销的需求、以及战略交易中的固有风险，例如未能实现预期利益的可能性、适用司法管辖区内的法律、监管或政治变化、会计和质量控制、可能超出预计资源分配以开发和商业化技术的风险、或未能维持任何实验室认证或许可的风险。

Actual results may differ materially from the results anti.

实际结果可能与预期结果存在重大差异。

CONTACT:

联系人：

Jeff Ramson

杰夫·拉姆森

PCG Advisory

PCG咨询

(646) 863-6893

(646) 863-6893

jramson@pcgadvisory.com

jramson@pcgadvisory.com